Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Cetuximab is named as an intervention in 112 current clinical trials in our China, USA, UK, Ireland and India registers. 77 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Revolution Medicines, Inc (8). The most-studied condition is Colorectal Cancer. The EU clinical trials register (CTIS) separately lists 7 authorised or ongoing trials, 1 with a site in Ireland.

Trials by status

Recruiting7769%
Not yet open1110%
Active, closed2321%
By invitation11%

Trials by phase

Phase 23430%
Phase 12926%
Phase 32522%
Phase 1/22421%

Clinical trials of Cetuximab

112 trials

Study	Phase	Status	Lead sponsor	Registers
Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases NCT04687631 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases	Phase 3	Recruiting	Fudan University	China
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC NCT04892173 · ClinicalTrials.gov ↗ · Carcinoma, Squamous Cell	Phase 3	Recruiting	Johnson & Johnson Enterprise Innovation Inc.	UK, USA, India, China
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer NCT05253651 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	Ireland, UK, USA, China
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN NCT05751512 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of the Head and Neck	Phase 3	Recruiting	Lepu Biopharma Co., Ltd.	China
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma NCT06064877 · ClinicalTrials.gov ↗ · Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma	Phase 3	Recruiting	AVEO Pharmaceuticals, Inc.	UK, USA, China
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer NCT06662786 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, India, China
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy NCT06750094 · Colorectal Neoplasms	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, India, China
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) NCT06881784 · NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC	Phase 3	Recruiting	Revolution Medicines, Inc.	Ireland, UK, USA
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) NCT06997497 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma, Rectal Adenocarcinoma	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) NCT07252232 · ClinicalTrials.gov ↗ · Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 3	Recruiting	Revolution Medicines, Inc.	UK, USA
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer NCT07262567 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer	Phase 3	Recruiting	Genfleet Therapeutics (Shanghai) Inc.	China
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma NCT07491445 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC	Phase 3	Recruiting	Revolution Medicines, Inc.	UK, USA, China
SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC NCT07549399 · ClinicalTrials.gov ↗ · Rectal Adenocarcinoma, High-Risk Cancer, MSS	Phase 3	Recruiting	Sixth Affiliated Hospital, Sun Yat-sen University	China
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation NCT07668752 · ClinicalTrials.gov ↗ · KRAS G12D Mutation, NSCLC (Non-small Cell Lung Cancer)	Phase 3	Recruiting	Genfleet Therapeutics (Shanghai) Inc.	China
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) NCT07702032 · Left-sided Colorectal Cancer	Phase 3	Recruiting	Genmab	USA
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma NCT07805954 · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC	Phase 3	Recruiting	Revolution Medicines, Inc.	USA
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN NCT05260671 · ClinicalTrials.gov ↗ · Head and Neck Neoplasms, Recurrent Disease, Metastatic Cancer	Phase 2	Recruiting	Eye & ENT Hospital of Fudan University	China
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer NCT05628038 · ClinicalTrials.gov ↗ · Recurrent Rectal Cancer	Phase 2	Recruiting	Fudan University	China
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma NCT06151743 · ClinicalTrials.gov ↗ · Locally Advanced Hypopharyngeal Carcinoma	Phase 2	Recruiting	Eye & ENT Hospital of Fudan University	China
Neoadjuvant SBRT in Localized Advanced HNSCC NCT06306846 · ClinicalTrials.gov ↗ · Head and Neck Squamous Carcinoma	Phase 2	Recruiting	Jiang Feng	China
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab NCT06540326 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study NCT06547203 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	Sun Yat-sen University	China
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM NCT06590259 · ClinicalTrials.gov ↗ · Colorectal Cancer Liver Metastasis	Phase 2	Recruiting	Shanghai 6th People's Hospital	China
Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer NCT06603376 · ClinicalTrials.gov ↗ · Colorectal Carcinoma	Phase 2	Recruiting	Shanghai Changzheng Hospital	China
Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer NCT06763029 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	Fudan University	China
Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC NCT06935188 · ClinicalTrials.gov ↗ · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	China
Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC NCT06978829 · ClinicalTrials.gov ↗ · LA HNSCC	Phase 2	Recruiting	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	China
Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer. NCT07044921 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	Chinese PLA General Hospital	China
IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation NCT07198841 · ClinicalTrials.gov ↗ · Lung Cancer (Non-Small Cell)	Phase 2	Recruiting	Guangdong Association of Clinical Trials	China
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) NCT07209111 · ClinicalTrials.gov ↗ · Neoplasm Malignant	Phase 2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) NCT07252739 · ClinicalTrials.gov ↗ · Malignant Neoplasm	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, China
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies NCT07415031 · Solid Tumors	Phase 2	Recruiting	Mirati Therapeutics Inc.	UK, USA, China
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer NCT07474727 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Multitude Therapeutics Inc.	China
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, USA, China
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer NCT07506109 · ClinicalTrials.gov ↗ · BRAF V600E, Colorectal Cancer, Sintilimab	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer NCT07644559 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS	Phase 2	Recruiting	Verastem, Inc.	USA
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer NCT07659795 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Verastem, Inc.	USA
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial NCT07722754 · ClinicalTrials.gov ↗ · Colorectal Neoplasms Malignant, Neoplasm, Metastatic	Phase 2	Recruiting	Guangdong Provincial People's Hospital	China
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation NCT05410145 · ClinicalTrials.gov ↗ · KRAS P.G12C	Phase 1/2	Recruiting	D3 Bio (Wuxi) Co., Ltd	USA, China
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors NCT05584670 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	Sanofi	USA
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis	Phase 1/2	Recruiting	Institut de Recherches Internationales Servier	China
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors NCT06128551 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Revolution Medicines, Inc.	USA
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors NCT06445062 · Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Revolution Medicines, Inc.	USA
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations NCT06500676 · ClinicalTrials.gov ↗ · KRAS G12D Mutations, Advanced Solid Tumors	Phase 1/2	Recruiting	Genfleet Therapeutics (Shanghai) Inc.	China
Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer NCT06776757 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 1/2	Recruiting	Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center	China
AK129 Combination Therapy for Advanced Solid Tumors NCT06943820 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma	Phase 1/2	Recruiting	Akeso	China
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC NCT07012954 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 1/2	Recruiting	Sun Yat-sen University	China
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors NCT07020221 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer	Phase 1/2	Recruiting	Verastem, Inc.	USA
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer NCT07059221 · ClinicalTrials.gov ↗ · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies NCT07223047 · ClinicalTrials.gov ↗ · Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)	Phase 1/2	Recruiting	Bristol-Myers Squibb	USA
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) NCT07286149 · Lung Neoplasm Malignant	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors NCT07397338 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC)	Phase 1/2	Recruiting	Revolution Medicines, Inc.	USA
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments NCT07468071 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation	Phase 1/2	Recruiting	Novartis Pharmaceuticals	China
HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer NCT07790510 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC)	Phase 1/2	Recruiting	Haisco Pharmaceutical Group Co., Ltd.	China
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) NCT04929223 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 1	Recruiting	Hoffmann-La Roche	UK, USA
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) NCT05067283 · Advanced Solid Tumors	Phase 1	Recruiting	Merck Sharp & Dohme LLC	USA, China
A Study of ASP3082 in Adults With Advanced Solid Tumors NCT05382559 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Recruiting	Astellas Pharma Inc	USA, China
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation NCT05504278 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer	Phase 1	Recruiting	Innovent Biologics (Suzhou) Co. Ltd.	China
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors NCT05836324 · Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors	Phase 1	Recruiting	Incyte Corporation	UK, USA, China
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation NCT06179160 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 1	Recruiting	Incyte Corporation	USA
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors NCT06241456 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	Fate Therapeutics	USA
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors NCT06332170 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	Hansoh BioMedical R&D Company	China
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) NCT06551142 · ClinicalTrials.gov ↗ · Neoplasms	Phase 1	Recruiting	GlaxoSmithKline	UK, USA
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors NCT06586515 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Recruiting	Eli Lilly and Company	Ireland, USA, China
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies NCT06720987 · ClinicalTrials.gov ↗ · KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies	Phase 1	Recruiting	Kumquat Biosciences Inc.	USA
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors NCT06764771 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors	Phase 1	Recruiting	Bristol-Myers Squibb	USA
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors NCT06797336 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Recruiting	PAQ Therapeutics, Inc.	USA
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations NCT06835569 · ClinicalTrials.gov ↗ · Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer)	Phase 1	Recruiting	Alterome Therapeutics, Inc.	USA
BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 1	Recruiting	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	USA
Study of AUBE00 in Patients With Solid Tumors NCT07030959 · Solid Tumors	Phase 1	Recruiting	Chugai Pharmaceutical	USA
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors NCT07216105 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer	Phase 1	Recruiting	Fate Therapeutics	USA
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) NCT07247110 · Malignant Neoplasm	Phase 1	Recruiting	Merck Sharp & Dohme LLC	USA
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors NCT07300150 · Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer	Phase 1	Recruiting	PAQ Therapeutics, Inc.	USA
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805 · ClinicalTrials.gov ↗ · Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer	Phase 1	Recruiting	Pfizer	USA
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors NCT07349537 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma	Phase 1	Recruiting	Revolution Medicines, Inc.	USA
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation NCT07535112 · Advanced/Metastatic Colorectal Adenocarcinoma	Phase 1	Recruiting	Bayer	USA
A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects NCT07813468 · ClinicalTrials.gov ↗ · Cetuximab, Bioequivalence, Healthy Volunteers	Phase 1	Recruiting	HC Biopharma Inc.	China
First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study NCT06616259 · ClinicalTrials.gov ↗ · Colorectal Cancer (CRC), Capecitabine, Cetuximab	Phase 3	Not yet open	Meng Qiu	China
Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC NCT07509099 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck	Phase 3	Not yet open	Ji Dongmei	China
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma NCT07768189 · ClinicalTrials.gov ↗ · Oropharyngeal Carcinoma (OPC)	Phase 3	Not yet open	Corbus Pharmaceuticals Inc.	UK, USA
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC NCT05993858 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy	Phase 2	Not yet open	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer NCT07000305 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer	Phase 2	Not yet open	Tao Zhang	China
Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer NCT07059338 · ClinicalTrials.gov ↗ · HER2 Positive, Colorectal Cancer (CRC)	Phase 2	Not yet open	Sun Yat-sen University	China
Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC NCT07070713 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy	Phase 2	Not yet open	Fujian Cancer Hospital	China
Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma NCT07079410 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma, Resectable Oral and Oropharyngeal Squamous Cell Carcinoma	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer NCT07554859 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 2	Not yet open	Genfleet Therapeutics (Shanghai) Inc.	China
A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation NCT07784374 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Not yet open	Genfleet Therapeutics (Shanghai) Inc.	China
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation NCT07678593 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation	Phase 1/2	Not yet open	Genfleet Therapeutics (Shanghai) Inc.	China
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression NCT07618624 · ClinicalTrials.gov ↗ · Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer	Phase 2	By invitation	Sun Yat-sen University	China
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer NCT00956007 · ClinicalTrials.gov ↗ · Head and Neck Cancer	Phase 3	Active, closed	Radiation Therapy Oncology Group	Ireland, China
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) NCT04008030 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, China
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer NCT04590963 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of the Head and Neck	Phase 3	Active, closed	AstraZeneca	UK, USA
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer NCT04607421 · Neoplasms	Phase 3	Active, closed	Pfizer	UK, USA, India, China
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) NCT04793958 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer, Metastatic Colorectal Cancer	Phase 3	Active, closed	Mirati Therapeutics Inc.	Ireland, UK, USA, China
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) NCT05239741 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	China
Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer NCT03391843 · ClinicalTrials.gov ↗ · Rectal Cancer Stage III	Phase 2	Active, closed	RenJi Hospital	China
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer NCT05217446 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Active, closed	Pfizer	UK, USA
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies NCT05226871 · ClinicalTrials.gov ↗ · Breast Cancer, Head and Neck Cancer	Phase 2	Active, closed	Pfizer	USA, China
AK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma NCT06508606 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Active, closed	West China Hospital	China
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors NCT02671435 · Advanced Solid Tumors	Phase 1/2	Active, closed	MedImmune LLC	UK, USA
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 NCT03785249 · Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease	Phase 1/2	Active, closed	Mirati Therapeutics Inc.	USA
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) NCT04956640 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms	Phase 1/2	Active, closed	Eli Lilly and Company	USA
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation NCT05194995 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer	Phase 1/2	Active, closed	Allist Pharmaceuticals, Inc.	China
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation NCT05358249 · ClinicalTrials.gov ↗ · KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung	Phase 1/2	Active, closed	Novartis Pharmaceuticals	USA
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation NCT06385678 · ClinicalTrials.gov ↗ · Advanced KRAS G12D Mutant Solid Tumors	Phase 1/2	Active, closed	Jiangsu HengRui Medicine Co., Ltd.	China
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation NCT04449874 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors	Phase 1	Active, closed	Genentech, Inc.	UK, USA
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers NCT04485013 · ClinicalTrials.gov ↗ · Cancer	Phase 1	Active, closed	Tizona Therapeutics, Inc	USA
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. NCT05355701 · ClinicalTrials.gov ↗ · Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer	Phase 1	Active, closed	Pfizer	USA
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors NCT06607185 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Active, closed	Eli Lilly and Company	USA
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone NCT06806852 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 1	Active, closed	Boehringer Ingelheim	UK, USA
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation NCT06818812 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 1	Active, closed	Incyte Corporation	USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Cetuximab in the EU trials register (CTIS)

7 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Cetuximab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors 2025-524623-50-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Revolution Medicines Inc	Ireland + 8 more
Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent Studies Investigating Adagrasib (BMS-986503) 2025-524905-34-00 · Neoplasms	Phase 2	Ongoing	Bristol-Myers Squibb Services Unlimited Company	Greece, Hungary, Poland + 8 more
Protocol Title: KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations 2024-512248-47-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Merck Sharp & Dohme LLC	Italy, Germany, Greece + 3 more
Fluorescence Intraoperative Surgical Margin Analysis in Head and Neck Cancer: Clinical Validation 2025-522027-95-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Universitair Medisch Centrum Groningen	Netherlands
Randomized study to compare first-line treatment with either continuous or intermittent cetuximab plus FOLFIRI in patients with RAS/BRAF-wild-type metastatic colorectal cancer (mCRC): AIO-KRK-0524 / FIRE-11 2025-522377-12-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Charite Universitaetsmedizin Berlin KöR	Germany
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial 2025-521209-42-00 · CTIS ↗ · Neoplasms	Phase 4	Authorised	Fondazione GONO G.I	Italy, Germany, Spain
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012). 2024-517232-22-00 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	Merck Sharp & Dohme LLC	Poland, Spain, Netherlands + 6 more

Cetuximab across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

1 single-substance product containing Cetuximab on the HPRA medicines list.

ErbituxMerck Europe B.V. · EU/1/04/281/001

All 1 Irish product →

Supply shortages

No entry for Cetuximab in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Cetuximab

122 conditions

Colorectal Cancer13 Advanced Solid Tumors7 Non-Small Cell Lung Cancer6 Solid Tumors6 Pancreatic Ductal Adenocarcinoma6 Pancreatic Cancer5 PDAC - Pancreatic Ductal Adenocarcinoma5 Colorectal Neoplasms5 Metastatic Colorectal Cancer5 Colorectal Cancer Metastatic5 PDAC4 Colorectal Cancer (CRC)4

All 122 conditions

Condition (as registered)	Trials
Colorectal Cancer	13
Advanced Solid Tumors	7
Non-Small Cell Lung Cancer	6
Solid Tumors	6
Pancreatic Ductal Adenocarcinoma	6
Pancreatic Cancer	5
PDAC - Pancreatic Ductal Adenocarcinoma	5
Colorectal Neoplasms	5
Metastatic Colorectal Cancer	5
Colorectal Cancer Metastatic	5
PDAC	4
Colorectal Cancer (CRC)	4
Solid Tumor	4
NSCLC (Non-small Cell Lung Cancer)	3
NSCLC	3
Non-small Cell Lung Cancer (NSCLC)	3
Pancreatic Ductal Adenocarcinoma (PDAC)	3
Non-small Cell Lung Cancer	3
Advanced Colorectal Cancer	3
Head and Neck Cancer	3
Head and Neck Squamous Cell Carcinoma	3
Advanced Solid Tumor	3
CRC (Colorectal Cancer)	3
Pancreatic Cancer Metastatic	2
Metastatic Solid Tumors	2
Neoplasms	2
Recurrent Head and Neck Squamous Cell Carcinoma	2
Rectal Adenocarcinoma	2
Squamous Cell Carcinoma of the Head and Neck	2
Malignant Neoplasm	2
Metastatic Cancer	2
Breast Cancer	2
Carcinoma, Non-Small-Cell Lung	2
Cancer	2
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	2
Cetuximab	2
NSCLC (Non-small Cell Lung Carcinoma)	1
Resectable Pancreatic Ductal Adenocarcinoma (PDAC)	1
Non-Small Cell Lung Cancer (NSCLC)	1
Pancreatic Adenocarcinoma	1
Carcinoma, Squamous Cell	1
Metastatic Head-and-neck Squamous-cell Carcinoma	1
Colon Adenocarcinoma	1
Neoplasm Malignant	1
Oropharyngeal Carcinoma (OPC)	1
CRC	1
Advanced Cancer	1
Malignant Neoplastic Disease	1
Advanced/Metastatic Colorectal Adenocarcinoma	1
Left-sided Colorectal Cancer	1
Lung Neoplasm Malignant	1
G12D Mutated KRAS	1
Ovarian Cancer	1
KRAS G12C Mutation	1
KRAS G12S Mutation	1
Solid Tumor Malignancies	1
KRAS G12C Mutant Solid Tumors	1
Carcinoma, Non-Small Cell Lung	1
Endometrial Neoplasms	1
Ovarian Neoplasms	1
Advanced Solid Malignancies	1
KRAS P.G12C	1
Melanoma	1
Non-Small-Cell Lung Cancer	1
Thyroid Cancer	1
Glioma	1
Non Small Cell Lung Cancer	1
Solid Tumor, Adult	1
Advanced Malignant Tumors	1
Advanced Breast Cancer	1
Metastatic Breast Cancer (HR+/ HER2-)	1
Metastatic Colorectal Adenocarcinoma	1
Recurrent Rectal Cancer	1
Lung Cancer (Non-Small Cell)	1
Metastatic Colorectal Cancer (CRC)	1
BRAF V600E	1
Sintilimab	1
MSS (Microsatellite Stable)	1
Rectal Cancer Stage III	1
High-Risk Cancer	1
MSS	1
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer	1
Advanced Solid Tumors Harboring the KRAS G12C Mutation	1
Liver Metastases	1
Head and Neck Squamous Carcinoma	1
Histiocytic Neoplasm	1
Histiocytosis	1
BRAF Gene Mutation	1
HER2 Positive	1
Advanced Solid Tumors Cancer	1
RAS Mutation	1
Colorectal Neoplasms Malignant	1
Neoplasm, Metastatic	1
Colorectal Cancer Liver Metastasis	1
NSCLC (Advanced Non-small Cell Lung Cancer)	1
Metastatic Colorectal Cancer With Left-sided Primary Tumor	1
Immunotherapy	1
Advanced KRAS G12D Mutant Solid Tumors	1
Small Intestinal Cancer	1
Appendiceal Cancer	1
Bioequivalence	1
Healthy Volunteers	1
Pharmacokinetics	1
Non-small Cell Lung Cancer Stage IIIB/IV	1
Head and Neck Squamous Cell Carcinoma (HNSCC)	1
Colorectal Adenocarcinoma	1
Neoadjuvant Therapy	1
Colorectal Carcinoma	1
Oral Squamous Cell Carcinoma (OSCC)	1
Oropharyngeal Squamous Cell Carcinoma	1
Resectable Oral and Oropharyngeal Squamous Cell Carcinoma	1
Advanced Non-Small Cell Lung Cancer	1
Locally Advanced Hypopharyngeal Carcinoma	1
LA HNSCC	1
Capecitabine	1
Squamous Cell Carcinoma of Head and Neck	1
Solid Cancer	1
Head and Neck Neoplasms	1
Recurrent Disease	1
KRAS G12D Mutation	1
Metastatic Pancreatic Cancer	1
KRAS G12D Mutations	1

By country register

Register	Trials	Recruiting
Clinical trials in China	71	49
Clinical trials in USA	62	45
Clinical trials in UK	23	14
Clinical trials in Ireland	7	4
Clinical trials in India	4	3
EU register (CTIS)	7	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Cetuximab trials

How many clinical trials are testing Cetuximab?

112 current trials in our China, USA, UK, Ireland and India registers name Cetuximab (also registered as GFH375) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Cetuximab trials recruiting patients?

Yes. 77 of the 112 trials are recruiting: 49 with sites in China, 45 with sites in USA, 14 with sites in UK, 4 with sites in Ireland and 3 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Cetuximab clinical trials?

Revolution Medicines, Inc (8), Merck Sharp & Dohme LLC (7), Genfleet Therapeutics (Shanghai) Inc (6) and Pfizer (5), among 69 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Cetuximab clinical trials in Ireland?

Yes. 7 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Cetuximab licensed in Ireland?

Yes. The HPRA medicines list includes 1 single-substance product containing Cetuximab, for example Erbitux (Merck Europe B.V.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Cetuximab shortage?

Not in the lists we track: Cetuximab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cetuximab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cetuximab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cetuximab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Cetuximab clinical trials